MAP4 antibodies are immunoreagents designed to detect and quantify MAP4, a 121 kDa protein (observed molecular weight: 210–240 kDa due to glycosylation) involved in microtubule dynamics. These antibodies are broadly used in research to:
Localize MAP4 in cellular compartments (e.g., cytoplasm, organelles) .
Study phosphorylation-dependent interactions (e.g., GSK3β-mediated regulation) .
Explore MAP4's role in diseases such as cancer and cardiovascular disorders .
MAP4 antibodies are validated for multiple techniques across human, mouse, and rat samples:
Organelle Transport: MAP4 phosphorylation by GSK3β biases organelle transport toward microtubule minus-ends by impairing kinesin-1 force generation .
Mitophagy Regulation: Phosphorylated MAP4 (p-MAP4) undergoes self-degradation via mitophagy, mediated by BH3 and LC3-interacting regions, influencing keratinocyte migration during wound healing .
Cancer:
Cardiovascular Effects: p-MAP4 disrupts endothelial cell mitochondria, reducing cardiac microvascular density and impairing angiogenesis .
Specificity: MAP4 antibodies target epitopes in the C-terminal microtubule-binding domain (e.g., aa 1100–C-terminus) or N-terminal projection domain .
Validation:
Storage: Stable at -20°C in PBS with 50% glycerol; avoid freeze-thaw cycles .
Isoform Diversity: Alternative splicing generates striated muscle-specific MAP4 isoforms (mMAP4), which regulate microtubule architecture and force generation in myofibers .
Therapeutic Potential: Inhibiting MAP4 phosphorylation enhances paclitaxel sensitivity in ovarian cancer, highlighting its role in chemoresistance .
KEGG: spo:SPBC21D10.06c
STRING: 4896.SPBC21D10.06c.1
MAP4 (microtubule-associated protein 4) is a non-neuronal protein that plays crucial roles in cell division and cytoskeleton organization. In humans, the canonical protein consists of 1152 amino acid residues with a molecular mass of approximately 121 kDa and localizes to the cytoplasm. MAP4 is widely expressed across numerous tissue types, making it a significant target for studying basic cellular processes . Unlike its neuronal counterparts (MAP1 and MAP2), MAP4 serves as a key regulator of microtubule dynamics in non-neuronal cells, influencing cell division, intracellular transport, and cellular architecture maintenance.
Up to seven different isoforms have been reported for MAP4 protein . Research should specifically differentiate between muscle MAP4 (mMAP4) and ubiquitous MAP4 (uMAP4) isoforms, as they demonstrate different binding properties to tubulin. In experimental design, researchers should explicitly state which isoforms they are targeting and consider how splice variants might influence their results. When selecting antibodies, determine whether the epitope is conserved across isoforms or specific to particular variants, as this will significantly impact interpretation of results .
Most commercial MAP4 antibodies show reactivity with human, mouse, and rat samples . MAP4 gene orthologs have been documented in mouse, rat, bovine, chimpanzee, and chicken species . When selecting an antibody for cross-species applications, researchers should examine sequence homology in the epitope region to predict potential cross-reactivity. Validation experiments are essential when using an antibody in species not explicitly listed in manufacturer specifications.
| Application | Common Dilutions | Sample Preparation | Detection Methods | Critical Controls |
|---|---|---|---|---|
| Western Blot | 1:250-1:1000 | Denatured protein lysates | Chemiluminescence or fluorescence | Positive control tissue, loading control |
| Immunohistochemistry | 1:100-1:500 | Fixed tissue sections | DAB or fluorescence | Isotype control, knockout tissue |
| Immunofluorescence | 1:100-1:250 | Fixed/permeabilized cells | Fluorescence microscopy | Secondary-only control |
| ELISA | 1:1000-1:5000 | Purified protein or lysate | Colorimetric or fluorometric | Standard curve, blank wells |
Each application requires optimization of antibody concentration, incubation conditions, and detection methods. For MAP4 detection, researchers commonly employ techniques such as Western Blot, Immunohistochemistry (IHC), Immunocytochemistry (ICC), and ELISA, with IHC being particularly widely used .
Antibody validation is crucial for reliable results. For MAP4 antibodies, a multi-step validation approach is recommended:
Specificity testing: Compare staining patterns between wild-type and MAP4 knockout or knockdown samples .
Phospho-specific validation: For phosphorylated MAP4 detection, compare results with and without phosphatase treatment.
Cross-application validation: Confirm consistent protein detection across different techniques (e.g., WB, IHC).
Epitope mapping: Understand exactly which region of MAP4 the antibody recognizes, particularly important given the multiple isoforms.
Reproducibility assessment: Batch-to-batch comparison when using the same antibody over extended research periods.
Document all validation steps methodically to ensure reproducibility and reliable interpretation of results in subsequent experiments.
Based on experimental protocols in recent literature, an effective methodology for MAP4 immunoprecipitation involves:
Prepare protein A/G magnetic beads (300 μL) by washing in PBST and incubating with anti-MAP4 antibody (90 μg) for 1 hour at room temperature .
Lyse tissue samples (e.g., gastroc muscles) according to standard protocols.
Incubate lysates with antibody-bound beads overnight at 4°C with rotation.
Wash beads three times with PBST, using a magnetic rack to separate beads from supernatant.
For tubulin-binding assays, incubate beads with 10 μM Rhodamine-labeled tubulin in appropriate buffer with 1 mM GTP for 30 minutes at 37°C .
After incubation, wash three times with PBST and elute proteins by boiling in sample buffer.
Analyze by SDS-PAGE and Western blotting or fluorescence detection.
This methodology has successfully demonstrated differential tubulin binding between MAP4 isoforms and can be adapted for various experimental conditions .
MAP4 undergoes phosphorylation at multiple sites, with Ser696 being particularly significant. Phosphorylation status affects MAP4's binding to microtubules and subsequently influences microtubule stability. Researchers should consider:
Phospho-specific antibodies: Using antibodies that specifically recognize phosphorylated forms (e.g., phospho-Ser696) in addition to total MAP4 antibodies .
Kinase/phosphatase treatments: Including experimental conditions that modulate phosphorylation status.
Physiological context: Interpreting results in light of known cell cycle or stress-dependent phosphorylation patterns.
Quantitative analysis: Calculating phosphorylated-to-total MAP4 ratios rather than absolute levels alone.
The phosphorylation state of MAP4 can dramatically alter experimental outcomes, particularly in studies of microtubule dynamics, cell division, or response to cellular stress.
Distinguishing MAP4 isoform functions requires sophisticated experimental approaches:
CRISPR-mediated genomic deletions: Generate isoform-specific knockout models by targeting specific exons (e.g., exon 8 deletion for mMAP4 elimination) .
RT-PCR with isoform-specific primers: Design primers targeting exon junctions (e.g., exon 6-7 junction forward primer: 5′-GGCTTCACCAGAACCAGTCA-3′ and exon-specific reverse primers) .
Immunoprecipitation with isoform-comparative analysis: Immunoprecipitate MAP4 from different tissues and compare functional properties like tubulin binding .
Tissue-specific expression analysis: Quantify relative abundance of different isoforms across tissue types.
Research has demonstrated that in skeletal muscle, the presence of mMAP4 significantly increases tubulin binding compared to uMAP4 alone (more than two-fold), highlighting the importance of isoform-specific analysis .
Advanced investigation of MAP4-dependent microtubule dynamics requires:
Live-cell imaging: Using fluorescently-tagged MAP4 constructs with simultaneous tubulin labeling.
FRAP (Fluorescence Recovery After Photobleaching): Measuring MAP4 turnover rates on microtubules.
Isoform-specific expression: Transfecting cells with specific MAP4 isoforms following endogenous MAP4 knockdown.
Phospho-mutant expression: Introducing phospho-mimetic or phospho-deficient MAP4 mutants.
Quantitative image analysis: Measuring microtubule growth rates, catastrophe frequencies, and rescue events in relation to MAP4 status.
These approaches enable researchers to dissect the dynamic interplay between MAP4 isoforms, post-translational modifications, and microtubule behavior in physiologically relevant contexts.
When facing contradictory results from different MAP4 antibodies, implement a systematic troubleshooting approach:
Epitope mapping comparison: Determine if antibodies recognize different domains or isoforms of MAP4.
Validation cross-checking: Verify each antibody's specificity using knockout/knockdown controls.
Application-specific testing: An antibody performing well in Western blots may fail in IHC due to epitope accessibility issues.
Database verification: Check the Antibody Registry for RRID validation and literature citations of each antibody .
Experimental condition normalization: Standardize fixation, antigen retrieval, and detection methods when comparing antibodies.
Independent technique confirmation: Verify key findings using non-antibody methods (e.g., mass spectrometry, RNA analysis).
Document all antibody information according to reproducibility standards, including catalog numbers and Research Resource Identifiers (RRIDs) for publication .
Proper statistical analysis of MAP4 data requires:
Normality testing: Determine if parametric or non-parametric tests are appropriate.
Multiple comparison correction: Apply Bonferroni or false discovery rate corrections when analyzing multiple conditions.
Paired analysis: Use paired tests when comparing treated vs. untreated samples from the same source.
Power analysis: Ensure adequate sample size based on expected effect size and variability.
Ratio analysis considerations: When analyzing phospho-to-total MAP4 ratios, apply appropriate transformations if ratios are not normally distributed.
Covariate analysis: Consider cell cycle stage, tissue type, or experimental conditions as covariates.
Statistical tests must be relevant to the specific analysis being performed, as emphasized in MAP4 research protocols .
MAP4 immunofluorescence experiments face several potential pitfalls:
Fixation artifacts: Microtubule preservation is highly sensitive to fixation methods. Use pre-warmed 4% paraformaldehyde for 10-15 minutes for optimal preservation.
Antibody cross-reactivity: MAP4 antibodies may cross-react with other MAPs. Validate specificity in cells with known MAP expression profiles.
Cell cycle variability: MAP4 distribution and phosphorylation change during the cell cycle. Consider synchronizing cells or co-staining for cell cycle markers.
Signal-to-noise challenges: Cytoplasmic localization can result in high background. Optimize blocking (3-5% BSA with 0.1% Triton X-100) and washing steps.
Quantification bias: When quantifying fluorescence intensity, establish unbiased sampling approaches and blind analysis.
Co-localization overinterpretation: Standard fluorescence microscopy has resolution limits. Confirm critical co-localization findings with super-resolution techniques.
Proper controls, including secondary-only staining, isotype controls, and competitive blocking with immunizing peptides, are essential for reliable MAP4 immunofluorescence data interpretation.
MAP4 dysregulation has been implicated in various pathological conditions. Research applications include:
Cancer research: Investigating MAP4's role in regulating mitotic spindles and cell proliferation.
Cardiac pathology: Studying how MAP4 phosphorylation affects cardiac microtubule stabilization during heart failure.
Neurodegenerative diseases: Examining potential interactions between MAP4 and neuronal MAPs in cellular models.
Developmental disorders: Assessing MAP4's role in proper cellular architecture during development.
Methodological considerations include using phospho-specific antibodies to detect disease-associated changes in MAP4 regulation and comparing isoform expression patterns between normal and pathological tissues.
Multiplexed detection of MAP4 alongside other proteins requires:
Antibody compatibility: Ensure primary antibodies are from different host species or use directly conjugated antibodies.
Spectral separation: Choose fluorophores with minimal spectral overlap for clear signal discrimination.
Sequential staining: Consider sequential rather than simultaneous staining for epitopes requiring different retrieval methods.
Cross-reactivity testing: Validate that secondary antibodies don't cross-react with inappropriate primaries.
Controls for each target: Include appropriate positive and negative controls for each protein in the multiplex panel.
Signal normalization: Develop strategies to normalize signal intensity across different antibodies.
Multiplexed approaches enable researchers to examine MAP4 in relation to other microtubule-associated proteins or cell cycle regulators within the same sample, providing valuable contextual information.